| Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response : genetic, epigenetic and clinical analyses | Molecular psychiatry |  | | 2025 | 7 | 165 |
|
| Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass | Obesity Surgery |  | | 2020 | 270 | 1 |
|
| Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients | American Journal of Transplantation | | | 2019 | 456 | 0 |
|
| Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances | Frontiers in Psychiatry | | | 2018 | 466 | 313 |
|
| Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia | Journal of Clinical Lipidology | | | 2017 | 535 | 168 |
|
| Association of genetic risk scores with body mass index in Swiss psychiatric cohorts | Pharmacogenetics and genomics | | | 2016 | 573 | 0 |
|
| Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments | Journal of clinical psychopharmacology | | | 2015 | 606 | 1 |
|
| Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments | Pharmacogenetics and genomics | | | 2015 | 668 | 0 |
|
| Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression | PloS one | | | 2015 | 619 | 256 |
|
| Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population | JAMA psychiatry | | | 2013 | 689 | 0 |
|
